New Report Unveils Hottest Industry Trends in Life Sciences Sector 2014
george james Ltd, a leading provider of recruitment, training and corporate development services to the scientific industry, has announced the availability of a new report “Life Science Trends 2014,” which outlines trends and innovations in the life sciences industry. Written in conjunction with Carlyle Conlan, the report encompasses drugs, biologics, devices and diagnostics sectors, summarising a variety of the most up to date industry news. It demonstrates significant advances in the industry from the past year and highlights observations about developments of interest throughout the year ahead. To obtain a free copy of the report please click here.
Designed as a meaningful “quick read” whitepaper, the report is separated into several macro headers: Research and Innovation, Fundamental Trends, Investing and Deal Making, Regulatory and Government and Health Care. The report is essential reading for those working in the pharmaceutical and biotech industries who are not only looking for an overall summary, but a resource to explore deeper, dependant on the individual interest of the reader.
In addition, the essential annual report also includes an exclusive feature article “Big Data in the Life Sciences”, which highlights commentary and interviews from several key senior industry professionals involved in big data breakthroughs in the life sciences sector. This feature article demonstrates how the enormous increase in data volume from segments like sequencing and systems biology, coupled with trends in pre-competitive data sharing and advanced computing frameworks, is in the early stages of providing robust signals, that will ultimately decrease the cost of drug development and maximise the industry’s return on investment.
Neil Burns, Founding Director at george james Ltd, said: “We are very pleased that this report has been published and is now easily available to download from our website. It has been structured in a way which is easy to read for industry professionals in pharma and biotech to keep informed but still can be researched further. We at george james strive help our customers achieve their core goals and specialisation and hope this report offers premium research of value to the life sciences sector.”
Don Alexander, Practice Head and Vice President, Life Sciences at Carlyle Conlan, comments: “We are very pleased to be able to, with the support of George James, have a report available for the public to read which covers such a wide range of articles across pertinent areas such as Health Care, Research and Innovation. What makes our report different is that an early version is sent to CEOs, venture capitalists and other industry experts for review before its final release and created using both primary and secondary data. We invite you to review the information contained in the report which we hope you will find relevant and interesting.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.